Print Page  Close Window

SEC Filings

EIGER BIOPHARMACEUTICALS, INC. filed this Form 8-K on 01/07/2019
Entire Document

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) Appointment of a New Director.

On January 7, 2019, our board of directors elected Christine Murray to serve on our board, until her successor is elected and qualified, or sooner in the event of her death, resignation or removal. Ms. Murray joins the class of directors whose term expires at our 2019 annual stockholders’ meeting. Our board of directors has determined that Ms. Murray meets the requirements for independence under the applicable listing standards of The Nasdaq Stock Market LLC and the Securities Exchange Act of 1934, as amended.

Ms. Murray will be entitled to receive compensation in accordance with our Non-Employee Director Compensation Policy, a copy of which is attached as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the period ended March 31, 2017, which was filed with the Securities and Exchange Commission on May 12, 2017. Ms. Murray also will enter into our standard form of indemnification agreement.

There are no arrangements or understandings between Ms. Murray and any other persons pursuant to which she was elected as a member of our board of directors. There are no family relationships between Ms. Murray and any director, executive officer, or any person nominated or chosen by us to become a director or executive officer. Ms. Murray is not a party to any current or proposed transaction with us for which disclosure is required under Item 404(a) of Regulation S-K.